No Data
Cathay Biotech Inc. (688065.SH): The controlling shareholder proposed the company to repurchase shares.
On October 16, Cathay Biotech Inc. (688065.SH) announced that the company's controlling shareholder, Cathay Industrial Biotech Ltd. (referred to as the 'controlling shareholder' or 'CIB'), issued a 'Letter on the Proposal for Cathay Biotech Inc. Shanghai to Repurchase Company Shares.' The controlling shareholder proposed that the company use its own funds to repurchase some of the RMB common shares (A shares) issued by Cathay Biotech Inc. Shanghai through the Shanghai Stock Exchange's trading system using centralized competitive bidding trading. The total amount of the repurchase funds shall not be less than RMB 10 million and not exceed RMB 20 million.
Cathay Biotech Inc. (688065.SH): The company develops bio-based polyamide composite materials, bio-based long-chain polyamide, and other products that can be applied to power batteries, energy storage, automobile thermal management components, etc.
Geelonghui September 18th | Cathay Biotech Inc. (688065.SH) stated on the investor interaction platform that new energy is one of the important application areas of the company's bio-based new materials. The company's developed bio-based polyamide composite materials, bio-based long-chain polyamide, and other products can be applied to power batteries, energy storage, autos' thermal management components, etc. At present, the company and its partners are jointly conducting product trial production and verification.
Cathay Biotech Inc. (688065.SH): Some ultra-long chain dicarboxylic acid varieties can be used for side chain modification of peptide drugs.
Gelonghui, September 18th, Cathay Biotech Inc. (688065.SH) stated on the investor interaction platform that some of the company's ultra-long-chain diacid varieties can be used for side chain modification of peptide drugs, providing long-acting sustained release effects. The company is also actively paying attention to related business opportunities, hoping to create more commercial value with its many years of technical accumulation in synthetic biology.
Cathay Biotech Inc. (688065.SH): Using synthetic biology technology to address the technical bottlenecks in the production process of pentamethylene diisocyanate from multiple angles.
Cathay Biotech Inc. (688065.SH) stated on the interactive platform on September 18 that after nearly ten years of research and development, the company has used synthetic biology technology to address technical bottlenecks in the production process of pentamethylene diisocyanate from multiple perspectives and has registered new substances with the Ministry of Ecology and Environment. Based on the pilot-scale pentamethylene diisocyanate production at its production base in Shandong, the company's 0.05 million ton per year bio-based pentamethylene diisocyanate production line at its Wusu base was put into operation in 2021, marking the first industrialization of pentamethylene diisocyanate products.
Cathay Biotech's (SHSE:688065) Anemic Earnings Might Be Worse Than You Think
Cathay Biotech's H1 Profit Rises 2%, Revenue Jumps 40%; Shares Down 3%
Investors Could Be Concerned With Cathay Biotech's (SHSE:688065) Returns On CapitalNo Data
No Data
